Sierra-Rodero, Belén https://orcid.org/0000-0003-0276-6088
Cruz-Bermúdez, Alberto https://orcid.org/0000-0001-5136-7011
Nadal, Ernest https://orcid.org/0000-0002-9674-5554
Garitaonaindía, Yago
Insa, Amelia
Mosquera, Joaquín
Casal-Rubio, Joaquín
Dómine, Manuel
Majem, Margarita https://orcid.org/0000-0002-9919-7485
Rodriguez-Abreu, Delvys
Martinez-Marti, Alex https://orcid.org/0000-0002-6714-9526
De Castro Carpeño, Javier
Cobo, Manuel
López Vivanco, Guillermo
Del Barco, Edel
Bernabé Caro, Reyes
Viñolas, Nuria
Barneto Aranda, Isidoro
Viteri, Santiago
Massuti, Bartomeu
Laza-Briviesca, Raquel
Casarrubios, Marta
García-Grande, Aránzazu
Romero, Atocha
Franco, Fernando
Provencio, Mariano https://orcid.org/0000-0001-6315-7919
Clinical trials referenced in this document:
Documents that mention this clinical trial
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
https://doi.org/10.1136/jitc-2022-005320
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009762
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
https://doi.org/10.1136/jitc-2021-002804
734 Tertiary lymphoid structures as hallmarks of response to neoadjuvant chemoimmunotherapy in locally advanced non-small cell lung cancer NADIM trial
https://doi.org/10.1136/jitc-2025-sitc2025.0734
Documents that mention this clinical trial
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
https://doi.org/10.1136/jitc-2022-005320
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009762
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
https://doi.org/10.1136/jitc-2021-002804
734 Tertiary lymphoid structures as hallmarks of response to neoadjuvant chemoimmunotherapy in locally advanced non-small cell lung cancer NADIM trial
https://doi.org/10.1136/jitc-2025-sitc2025.0734
Funding for this research was provided by:
Bristol-Myers Squibb
Spanish Lung Cancer Group
Horizon 2020 Framework Programme (CLARIFY 875160)
European Social Fund (PEJ16/MED/AI-1972, PEJD-2018-PRE/SAL-8641, PEJD-2019-PRE/BMD-17006)
Ministry of Science and Innovation (RTC2017-6502-1, RTC2019-007359-1)
ISCIII (CD19/00170, PI19/01652)